Case Report

Living Donor Liver Transplantation for Hepatic Venoocclusive Disease/Sinusoidal Obstruction Syndrome Originating from Hematopoietic Stem Cell Transplantation

Kentaro Ichimura,1 Norio Kawamura2,3 Ryoichi Goto,2 Masaaki Watanabe,2 Yoshikazu Ganchiku,2 Tsuyoshi Shimamura,3 and Akinobu Taketomi1

1Department of Gastroenterological Surgery I, Hokkaido University Hospital, Japan
2Department of Transplant Surgery, Hokkaido University Graduate School of Medicine, Japan
3Division of Organ Transplantation, Hokkaido University Hospital, Japan

Correspondence should be addressed to Norio Kawamura; norirv@live.jp

Received 18 March 2022; Accepted 9 May 2022; Published 21 May 2022

Academic Editor: Ryszard Grenda

Copyright © 2022 Kentaro Ichimura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Venoocclusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening hematopoietic stem cell transplantation (HSCT) complication. Cases of mild and moderate VOD/SOS are self-limiting; however, the mortality for severe VOD/SOS has reached 80%. Recently, defibrotide became available and has been used for VOD/SOS; however, the outcome for patients with severe VOD/SOS is not satisfactory, and liver transplantation is attempted in these severe cases. Method. We describe a case of living donor liver transplantation (LDLT) for acute liver failure secondary to VOD/SOS that originates from HSCT. Result. Liver regeneration after LDLT was impaired, and several infections were developed before liver regeneration completion. Our patient suffered sepsis and finally died of multiorgan failure. Conclusion. Severe VOD/SOS originating from HSCT is associated with a very poor prognosis. The liver transplantation outcome for VOD/SOS has not been satisfied, but it may provide long-term survival if successful. We considered liver transplantation as a therapeutic option, especially in cases where sufficient graft volume is secured, considering impaired liver regeneration under bone marrow suppression after HSCT.

1. Introduction

Venoocclusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening hematopoietic stem cell transplantation (HSCT) complication. A myeloablative preparative regimen, using busulfan (BU), cyclophosphamide (CY), and total body irradiation (TBI), increases the risk of VOD/SOS [1]. Cases of mild and moderate VOD/SOS are self-limiting; however, the mortality for severe VOD/SOS has reached 80% [1, 2]. Recently, defibrotide became available and has been used for VOD/SOS. However, satisfactory results have not yet been achieved with defibrotide in cases with severe VOD/SOS, such as those with acute liver failure, and liver transplantation is attempted in these severe cases. Here, we describe a case of living donor liver transplantation (LDLT) for acute liver failure secondary to VOD/SOS originating from HSCT.

2. Case Report

A 7-year-old female patient has been initially diagnosed with B-cell precursor acute lymphoblastic leukemia (B-ALL) with hyperdiploidy, which was known to have a favorable prognosis. She underwent combination chemotherapy and achieved initial complete remission. Relapse occurred 6 years following the completion of 2-year chemotherapy, after which combination therapy was repeated, and a second complete remission was achieved. Allogeneic HSCT from a human leukocyte antigen- (HLA-) matched sibling donor was planned when she was 16 years old. Myeloablative
preparative chemoradiotherapy, including etoposide at 1800 mg/sqm, CY at 120 mg/kg, and TBI at 12 Gy in six fractions, was performed before HSCT. The patient received an intravenous infusion of bone marrow cells (a total of $3.27 \times 10^9$/kg, including $2.3 \times 10^6$/kg as CD34+ cells). Short-term methotrexate (15 mg on day +1 and 10 mg on day +3, +6, and +11) and cyclosporine A (3.0 mg/kg) daily from day -1 were used for graft-versus-host disease (GVHD).

On day +17 after HSCT, full-donor chimerism was detected using short tandem repeat analysis. However, she suffered weight gain, ascites, and hepatomegaly and had elevated liver enzymes on day +20 after HSCT. According to the European Society for Blood and Marrow Transplantation (EBMT) criteria, the diagnosis was VOD/SOS, moderate severity. Recombinant human soluble thrombomodulin (rhTM) therapy could not improve liver function.

On day +44 after HSCT, grade II hepatic encephalopathy and coagulopathy with a prothrombin time-international normalized ratio level of 3.0 developed, and the patient was diagnosed with acute liver failure secondary to VOD/SOS. VOD/SOS severity progressed to moderate to very severe. Defibrotide was unapproved in Japan at that time (2019/06-approved); thus, there were no other treatment options other than liver transplantation. Based on the achievement of complete chimera and an estimated 2-year recurrence rate of 0% [3], the decision was made to perform LDLT. Preoperative bone marrow aspiration revealed engraftment achievement, but lab tests showed pancytopenia despite daily GCSF administration (hemoglobin [Hb] of 7.7 g/dL, leukocytes of 3,700/L, and platelets of 49,000/L). LDLT was performed on day +84 after HSCT using a left lobe graft from her 46-year-old mother. The CT volumetry showed the total liver volume of donor was 886 cm$^3$, the graft weight was 294 g, and graft volume/standard liver volume ratio was 28%, and the graft-to-recipient weight ratio was 0.59%.

An enlarged liver with marked congestion and extensive collateral retroperitoneal circulation was found during surgery. Additionally, serosal sclerosis in the small intestine and mesentery indicated that the myeloablative preparative chemoradiotherapy influence extended to the liver. Histopathologic findings showed necrosis and hemorrhage in zone 3 and central vein obliteration, which were compatible with VOD/SOS (Figure 1).

No postoperative surgical complications occurred. A daily granulocyte-stimulating factor was administered to keep the white blood cell level at >5000/μL from postoperative days (POD) 1 to 18. Immunosuppression consisted of steroids and tacrolimus. Mycophenolate mofetil was not used because of myelosuppression. The steroid was started on POD 1, and tacrolimus was administered on POD 5. Immediately after LDLT, restrictive ventilatory impairment with widespread alveolar injury on chest radiography occurred. Cultures or other assays revealed the absence of bacterial, fungal, or viral infection.

Graft function was favorable until 3 weeks after LDLT, and total bilirubin decreased to 2.0 mg/dL. However, liver enzymes were gradually elevated after the granulocyte-stimulating factor was discontinued. A liver biopsy on POD 26 revealed hepatocyte ballooning and suggested small-for-size syndrome (SFSS) (Figure 2). Subsequently, her respiratory condition deteriorated due to atelectasis from pleural effusion and pneumonia. Several viral infections developed thereafter, including hemorrhagic cystitis due to BK virus and cytomegalovirus infection. Therefore, tacrolimus therapy was discontinued and only prednisolone was administered.
Afterward, skin rashes appeared on her trunk, and a skin biopsy revealed GVHD. Tacrolimus administration was resumed and GVHD improved; however, individualizing the immunosuppressant drug therapy and controlling the infections became very difficult. Infections led to graft dysfunction, and increased ascites caused infections. Several liver biopsies were performed, which showed no signs of rejection, but hepatocyte ballooning and bile duct damage were noticeable. Sepsis developed and she finally died of multiorgan failure (MOF) on day 119 after LDLT.

3. Discussion

VOD/SOS is a life-threatening complication following HSCT and is characterized by tender hepatomegaly, elevated serum bilirubin, and weight gain. Its reported mean incidence is 14% of patients following HSCT, but this varies among studies depending on the preparative regimen and diagnostic criteria [4]. The primary insult of this disease is the sinusoidal endothelial cell damage in zone 3 of the hepatic acinus [5]. This causes a circular disorder and non-thrombotic obstruction, which provokes fibrosis and sinusoidal portal hypertension, and finally leads to liver failure [4, 6]. According to the EBMT criteria for severity grading, our patient was classified as having very severe VOD/SOS [7]. Almost all cases of mild or moderate VOD/SOS are self-limiting and resolve within a few weeks, but the mortality rate for severe VOD/SOS is >80% [4].

Histologically, VOD/SOS treatment had included supportive care, but defibrotide has been currently highly recommended in Western guidelines. However, its outcome for severe VOD/SOS has not been promising [8, 9].

Defibrotide was not approved in Japan during this case (2019/6-approved). LDLT was decided because the prognosis seemed to be very poor with only conservative treatment, and this patient seemed to be a good candidate for liver transplantation other than graft size. Some reports have indicated performing liver transplantation in patients with VOD/SOS without original disease relapse, as well as evidence of bone marrow engraftment, absence of acute GVHD, and absence of severe other organ failures in those with a good original disease prognosis after HSCT [10]. Our patient fulfilled all of these indications.

There have been 17 reports on liver transplantation for VOD/SOS originating from HSCT (Table 1) [10–23]. Six (35%) patients survived longer than the follow-up period (9 months–8 years). The results have been unsatisfactory, especially in adults (3/15, 20%). In the meantime, three patients (all infants) underwent LDLT, and their day +100 survival rate was 100%. The result that the outcome of pediatric cases was superior to adult cases suggests that LDLT in infants would be preferable to that in adults. However, these results are speculated to be attributable to graft size and the regenerative potential in both liver and bone marrow, which made these results unclear.

Bone marrow progenitor of liver sinusoidal endothelial cells (BM sprocs) was recruited after liver injury and plays an important role in liver regeneration. BM sprocs provide hepatocyte growth factor, which stimulates driving hepatocytes toward proliferation [24]. Therefore, liver regeneration
is impaired under BM suppression, which might be consistent with some pediatric patients with acute liver failure simultaneously developing BM failure [25]. Additionally, Lee et al. suggested that BM sprocs originating from the recipient are most important for graft volume restoration in liver transplantation [26]. Therefore, liver regeneration after LDLT could be achieved only when bone marrow function is satisfactory. In adult LDLT cases, graft regeneration is necessary, especially in small graft cases, such as graft volume of <40%. Consistently, the LDLT outcome for VOD/SOS in an infant is preferable to that of an adult as mentioned because ensuring sufficient graft volume in an infant case is easy.

In our case, preoperative bone marrow aspiration achieved engraftment, but lab tests showed pancytopenia despite the daily GCSF administration (Hb of 7.7 g/dL, leukocytes of 3,700/L, and platelets of 49,000/L). This data indicated that our patient was still in the bone marrow recovery phase, and the bone marrow function was inadequate to regenerate a partial liver graft.

Among these 17 reported patients, 10 died of infection and/or MOF, suggesting that infection control is important in such patients. Especially, our patient may be managed with less immunosuppression in liver transplantation after HSCT because, first, our patient received allogeneic HSCT from an HLA-matched sibling donor. HLA allele mismatching is widely known as a significant risk factor for GVHD [27]; thus, our patient had the lowest risk of GVHD. Second, the risk of infections is more in recipients who undergo HSCT compared with those who do not. Immune system recovery following HSCT is a highly dynamic process, which begins with innate immunity resurgence within the first few weeks of HSCT, followed by adaptive immune system resurgence. The complete recovery of the latter may take 2 years or longer [28]. Particularly, our patient suffered from some viral infections; thus, we might be able to reduce steroids.

Once infections emerge, individualizing immunosuppressive drug therapy and controlling infections after the GVHD development is difficult. GVHD and its associated therapies result in profound immunosuppression [29], which could cause infection and exacerbate existing infections. Thus, continuous administration of immunosuppressive drugs even at a minimal dose in cases of active infection is considered important to prevent GVHD.

In summary, this patient was diagnosed with very severe VOD/SOS after HSCT. No other treatment option was available than liver transplantation because conservative therapy was unlikely to improve the condition. LDLT was performed, but finally, this patient died of MOF due to infections. A low dose of immunosuppression should be managed in liver transplantation after HSCT because these patients may be vulnerable to infection. After all, immune system recovery takes a long time. We had no choice but to perform LDLT with a small graft; however, securing a sufficient graft volume is important in liver transplantation for bone marrow failure because normal liver regeneration cannot be expected.

In conclusion, severe VOD/SOS is associated with a very poor prognosis. The outcome of liver transplantation for VOD/SOS has not been satisfactory but should be considered as a therapeutic option in case a sufficient graft volume can be secured because it may provide long-term survival if successful.

| LT type | Age/sex | Conditioning regimens | Time to LT (day) | Follow-up period status | Cause of death |
|---------|---------|------------------------|------------------|-------------------------|----------------|
| Case 1 (11) | Deceased | 55/F | CY/BU | 42 | 54 days | Death | Infection |
| Case 2 (12) | Deceased | 49/M | CY/BU | 31 | 31 days | Death | MOF |
| Case 3 (13) | Deceased | 47/M | CY/BU | 41 | 60 days | Death | Infection/MOF |
| Case 4 (14) | Deceased | 43/M | Etosposide/CY/carmustine | 22/44(1st/2nd) | 70 days | Death | Pneumonia, ARDS/TTP |
| Case 5 (13) | Deceased | 39/F | CY/BU | 79 | 62 days | Death | Aspergillosis/intracerebral hemorrhage/MOF |
| Case 6 (15) | Deceased | 38/M | CY/BU | 23 | 8 years | Alive |
| Case 7 (16) | Deceased | 35/M | CY/TBI | 43 | 9 months | Alive |
| Case 8 (17) | Deceased | 34/F | CY/BU | 21 | 1 year | Alive |
| Case 9 (18) | Deceased | 34/F | CY/BU | 35 | 42 days | Death | Interstitial pneumonitis/MOF |
| Case 10 (19) | Deceased | 33/M | CY/BU | 36 | 3 days | Death | Cerebral edema |
| Case 11 (19) | Deceased | 32/F | CY/TBI | 39 | 30 days | Death | Pneumonia |
| Case 12 (19) | Deceased | 31/F | CY/BU | 25 | 213 days | Death | Liver failure |
| Case 13 (20) | Deceased | 25/M | CY/BU | 32 | 6 months | Death | Pneumocystis pneumonia |
| Case 14 (21) | Deceased | 23/M | CY/BU | 80 | 140 days | Death | Infection |
| Case 15 (22) | Living | 2 m/F | CY/TBI | 33 | 9 months | Alive |
| Case 16 (23) | Living | 1/F | CY/BU | 84 | 29 months | Alive |
| Case 17 (10) | Living | 11 m/M | CY/BU/TBI | 42 | 17 months | Alive |
| Our case | Living | 16/F | CY/etosposide/TBI | 84 | 119 days | Death | Sepsis/MOF |

LT: Liver transplantation; Cy: Cyclophosphamide; BU: Busulfan; TBI: Total body irradiation; MOF: Multiorgan failure; ARDS: Acute respiratory distress syndrome; TTP: Thrombotic thrombocytopenic purpura.
Abbreviations

B-ALL: B-cell precursor acute lymphoblastic leukemia
BU: Busulfan
CY: Cyclophosphamide
EBMT: European Society for Blood and Marrow Transplantation
GVHD: Graft-versus-host disease
HSCT: Hematopoietic stem cell transplantation
LDLT: Living donor liver transplantation
MOF: Multiorgan failure
POD: Postoperative day
rhTM: Recombinant human soluble thrombomodulin
SFSS: Small-for-size syndrome
SOS: Sinusoidal obstruction syndrome
TBI: Total body irradiation
VOD: Venoocclusive disease.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We would like to thank the patient and her family in our study. This work is supported by the JSPS KAKENHI Grant number 19k18018.

References

[1] G. B. McDonald, M. S. Hinds, L. D. Fisher et al., "Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients," *Annals of Internal Medicine*, vol. 118, no. 4, pp. 255–267, 1993.

[2] D. C. Valla and D. Cazals-Hatem, "Sinusoidal obstruction syndrome," *Clinics and Research in Hepatology and Gastroenterology*, vol. 40, no. 4, pp. 378–385, 2016.

[3] X. Y. Qin, G. X. Li, Y. Z. Qin et al., "Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT," *Bone Marrow Transplantation*, vol. 49, no. 10, pp. 1269–1277, 2014.

[4] J. A. Coppell, P. G. Richardson, R. Soiffer et al., "Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome," *Biology of Blood and Marrow Transplantation*, vol. 16, no. 2, pp. 157–168, 2010.

[5] E. Carreras and M. Diaz-Ricart, "The role of the endothelium in the short-term complications of hematopoietic SCT," *Bone Marrow Transplantation*, vol. 46, no. 12, pp. 1495–1502, 2011.

[6] L. D. DeLeve, H. M. Shulman, and G. B. McDonald, "Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)," *Seminars in Liver Disease*, vol. 22, no. 1, pp. 027–042, 2002.

[7] S. Corbacioglu, E. Carreras, M. Ansari et al., "Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation," *Bone Marrow Transplantation*, vol. 53, no. 2, pp. 138–145, 2018.

[8] P. G. Richardson, C. Murakami, Z. Jin et al., "Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ fail-
ure: response without significant toxicity in a high-risk population and factors predictive of outcome," *Blood*, vol. 100, no. 13, pp. 4337–4343, 2002.

[9] K. Yakushijin, T. Ikezoe, C. Ohwada et al., "Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation," *Bone Marrow Transplantation*, vol. 54, no. 5, pp. 674–680, 2019.

[10] I. D. Kim, H. Egawa, Y. Marui et al., "A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation," *American Journal of Transplantation*, vol. 2, no. 8, pp. 796–800, 2002.

[11] C. Koencke, M. Kleine, H. Schrem et al., "Sinusoidal obstruction syndrome of the liver after hematopoietic stem cell transplantation: decision making for orthotopic liver transplantation," *International Journal of Hematology*, vol. 83, no. 3, pp. 271–274, 2006.

[12] G. C. Mac Quillan and D. Mutimer, "Fulminant liver failure due to severe veno-occlusive disease after haematopoietic cell transplantation: a depressing experience," *QJM*, vol. 97, no. 9, pp. 581–589, 2004.

[13] C. Salat, E. Holler, C. Wolf et al., "Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation," *Bone Marrow Transplantation*, vol. 19, no. 5, pp. 487–490, 1997.

[14] A. Dowlati, P. Honore, P. Damas et al., "Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation," *Transplantation*, vol. 60, no. 1, pp. 106–109, 1995.

[15] H. J. Schlitt, H. J. Tischler, B. Ringe et al., "Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation—clinical and immunological considerations," *Bone Marrow Transplantation*, vol. 16, no. 3, pp. 473–478, 1995.

[16] H. R. Rosen, P. Martin, G. J. Schiller et al., "Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver," *Liver Transplantation and Surgery*, vol. 2, no. 3, pp. 225–232, 1996.

[17] S. D. Nimer, A. L. Milewicz, R. E. Champlin, and R. W. Busuttil, "Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation," *Transplantation*, vol. 49, no. 4, pp. 819–821, 1990.

[18] A. P. Rapoport, H. R. Doyle, T. Starzl, J. M. Rowe, T. Doeblin, and J. F. DiPersio, "Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant," *Bone Marrow Transplantation*, vol. 8, no. 5, pp. 421–424, 1991.

[19] H. Häggblom, O. Ringdén, B. G. Ericzon et al., "Treatment of hepatic venoocclusive disease with recombinant human tissue plaminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation," *Transplantation*, vol. 62, no. 8, pp. 1076–1080, 1996.

[20] S. Norris, O. Crosbie, G. McEntee et al., "Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation," *Transplantation*, vol. 63, no. 10, pp. 1521–1524, 1997.

[21] F. E. Membreno, J. Ortiz, P. F. Foster et al., "Liver transplantation for sinusoidal obstructive syndrome (veno-occlusive disease): case report with review of the literature and the UNOS database," *Clinical Transplantation*, vol. 22, no. 4, pp. 397–404, 2008.
N. Bunin, A. Leahey, and S. Dunn, “Related donor liver transplant for veno-occlusive disease following T-depleted unrelated donor bone marrow transplantation,” *Transplantation*, vol. 61, no. 4, pp. 664–666, 1996.

K. Mellgren, A. Fasth, R. Saalman, M. Olausson, and J. Abrahamsson, “Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia,” *Annals of Hematology*, vol. 84, no. 11, pp. 755–757, 2005.

L. Wang, X. Wang, L. Wang et al., “Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells,” *Gastroenterology*, vol. 143, no. 6, pp. 1555–1563.e2, 2012.

L. D. DeLeve, X. Wang, and L. Wang, “VEGF-sdf1 recruitment of CXCR7+ bone marrow progenitors of liver sinusoidal endothelial cells promotes rat liver regeneration,” *American Journal of Physiology Gastrointestinal and Liver Physiology*, vol. 310, no. 9, pp. G739–G746, 2016.

S. G. Lee, S. H. Moon, H. J. Kim et al., “Bone marrow-derived progenitor cells in de novo liver regeneration in liver transplant,” *Liver Transplantation*, vol. 21, no. 9, pp. 1186–1194, 2015.

E. W. Petersdorf, T. A. Gooley, C. Anasetti et al., “Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient,” *Blood*, vol. 92, no. 10, pp. 3515–3520, 1998.

R. S. Mehta and K. Rezvani, “Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection,” *Virulence*, vol. 7, no. 8, pp. 901–916, 2016.

G. B. Vogelsang, L. Lee, and D. M. Bensen-Kennedy, “Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant,” *Annual Review of Medicine*, vol. 54, no. 1, pp. 29–52, 2003.